Hims & Hers ($HIMS) CEO Andrew Dudum and CMO Anant Vinjamoori Hail HHS Peptide Framework, Highlighting...

Following the U.S. Department of Health and Human Services' (HHS) interim directive allowing regulated compounding of previously restricted peptides, Hims & Hers Health ($HIMS) CEO Andrew Dudum and Chief Medical Officer Dr. Anant Vinjamoori issued official statements confirming that the company has spent years building domestic peptide manufacturing and clinical infrastructure to capitalize on the transition away from gray-market sellers.
Key executive remarks, vertical integration advantages, and product expansion signals include:
- CEO Andrew Dudum on Domestic Supply Chain Readiness: Welcoming the federal regulatory shift toward patient-specific prescriptions and ingredient traceability, Dudum stated, "HHS just took a step toward the exact future that we’ve built for – bringing peptides out of the gray market, with clinician oversight and quality starting at the source. We’ve taken it one step further by building a US-based supply chain and infrastructure that our customers can trust."
- CMO Dr. Anant Vinjamoori on In-House U.S. Peptide Facility: Highlighting the company's multi-year investment in domestic production and clinical protocols, Vinjamoori noted, "We have spent years building the infrastructure we need in our very own US-based peptide manufacturing facility, developing dosing protocols with clinical experts, and setting up frameworks to better understand these emerging treatments. This is encouraging progress. More to come."
- Competitive Moat and Product Launch Tease ("More to Come"): By operating its own U.S.-based peptide manufacturing facility alongside licensed telehealth clinician networks, Hims & Hers ($HIMS) is positioned to immediately meet HHS requirements for verified active pharmaceutical ingredients (APIs), quality testing, and safety reporting—signaling imminent commercial rollouts in longevity, recovery, and preventative health categories.